Best Practice & Research Clinical Rheumatology
Volume 20, Issue 1 , Pages 69-80 , February 2006

Do biochemical markers have a role in osteoarthritis diagnosis and treatment?

  • Virginia B. Kraus, PhD, MD (Associate Professor of Medicine)

      Affiliations

    • Corresponding Author InformationTel.: +1 919 681 6652; Fax: +1 919 684 8907.

References 

  1. Sunderland T. The prospective search for alzheimer's disease biomarkers. Biomarkers and Surrogate Endpoints: Advancing Clinical Research and Applications. Bethesda, MD: IOS Press; 1998;p. 194
  2. Schatzkin A, Freedman L, Schiffman M. An epidemiologic perspective on biomarkers. Journal of Internal Medicine. 1993;233(1):75–79
  3. Vignon E, Piperno M, Le Graverand MP, et al. Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: comparison of standing anteroposterior and lyon schuss views. Arthritis and Rheumatism. 2003;48(2):378–384
  4. Mazzuca SA, Brandt KD, Katz BP, et al. Comparison of quantitative and semi-quantitative indicators of joint space narrowing in subjects with knee osteoarthritis. Annals of the Rheumatic Diseases. 2005;26:26
  5. Bingham C, Aronstein W, Adami S, et al. Treatment with risedronate reduced urinary CTX-II, a specific biochemical marker of type II collagen degradation, in a 24-month study of knee OA. Osteoarthritis and Cartilage. 2004;12(supplement B):S9–M22
  6. King KB, Lindsey CT, Dunn TC, et al. A study of the relationship between molecular biomarkers of joint degeneration and the magnetic resonance-measured characteristics of cartilage in 16 symptomatic knees. Magnetic Resonance Imaging. 2004;22(8):1117–1123
  7. Ding C, Garnero P, Cicuttini F, et al. Knee cartilage defects: association with early radiographic osteoarthritis, decreased cartilage volume, increased joint surface area and type II collagen breakdown. Osteoarthritis and Cartilage. 2005;13(3):198–205
  8. Hunter D, Tu X, LaValley M, et al. Change in joint space width: hyaline cartilage loss or meniscal change. Arthritis and Rheumatism. 2004;50(supplement 9):1717;[S643]
  9. Garnero P, Mazieres B, Gueguen A, et al. Cross-sectional association of 10 molecular markers of bone, cartilage, and synovium with disease activity and radiological joint damage in patients with hip osteoarthritis: the ECHODIAH cohort. The Journal of Rheumatology. 2005;32(4):697–703
  10. Mildvan D, Landay A, De Gruttola V, et al. An approach to the validation of markers for use in AIDS clinical trials. Clinical Infectious Diseases. 1997;24(5):764–774
  11. Pepe M, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute. 2001;93(14):1054–1061
  12. http://www.nih.gov/niams/news/oisg/index.htm.
  13. Simkin PA, Bassett JE. Cartilage matrix molecules in serum and synovial fluid. Current Opinion in Rheumatology. 1995;7(4):346–351
  14. Clark AG, Jordan JM, Vilim V, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis and Rheumatism. 1999;42(11):2356–2364[comment]
  15. Garnero P, Sornay-Rendu E, Arlot M, et al. Association between spine disc degeneration and type II collagen degradation in postmenopausal women: the OFELY study. Arthritis and Rheumatism. 2004;50(10):3137–3144
  16. Elliott A, Kraus VB, Luta G, et al. Serum hyaluronan levels and radiographic osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis and Rheumatism. 2005;52(1):105–111
  17. Lohmander LS, Felson D. Can we identify a 'high risk' patient profile to determine who will experience rapid progression of osteoarthritis?. Osteoarthritis and Cartilage. 2004;12(supplement A):S49–S52
  18. Reijman M, Hazes JM, Bierma-Zeinstra SM, et al. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis and Rheumatism. 2004;50(8):2471–2478
  19. Elliott AL, Kraus VB, Luta G, et al. Serum hyaluronan levels and radiographic knee and hip osteoarthritis in African Americans and Caucasians in the Johnston County Osteoarthritis Project. Arthritis and Rheumatism. 2005;52(1):105–111
  20. Cole AA, Kuettner KE. Molecular basis for differences between human joints. Cellular Molecular Life Sciences. 2002;59(1):19–26
  21. Piscoya J, Fermor B, Kraus V, et al. The dose response relationship of mechanical compression on the induction of osteoarthritis-related biomarkers in articular cartilage explants. Osteoarthritis and Cartilage; 2005; in press.
  22. Garnero P, Ayral X, Rousseau JC, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis and Rheumatism. 2002;46(10):2613–2624
  23. Sharma L, Ionescu M, Song J, et al. The ratio of collagen breakdown to collagen synthesis and its relationship with the progression of knee osteoarthritis. Arthritis and Rheumatism. 2004;50(supplement 9):642;[see also S282]
  24. Saari H. Oxygen derived free radicals and synovial fluid hyaluronate. Annals of the Rheumatic Diseases. 1991;50(6):389–392
  25. Courel MN, Maingonnat C, Tranchepain F, et al. Importance of hyaluronan length in a hyaladherin-based assay for hyaluronan. Analytical Biochemistry. 2002;302(2):285–290
  26. Myers S, Brandt K, Eilam O. Even low-grade synovitis significantly accelerates the clearance of protein from the canine knee. Arthritis and Rheumatism. 1995;38(8):1085–1091
  27. Manicourt DH, Poilvache P, Nzeusseu A, et al. Serum levels of hyaluronan, antigenic keratan sulfate, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases 1 change predictably in rheumatoid arthritis patients who have begun activity after a night of bed rest. Arthritis and Rheumatism. 1999;42(9):1861–1869
  28. Mundermann A, Dyrby CO, Andriacchi TP, King KB. Serum concentration of cartilage oligomeric matrix protein (COMP) is sensitive to physiological cyclic loading in healthy adults. Osteoarthritis and Cartilage. 2005;13(1):34–38
  29. Criscione L, Elliott A, Stabler T, Jordan J. Variation of serum hyaluronan with activity in individuals with knee osteoarthritis. Osteoarthritis and Cartilage, in press.
  30. Neidhart M, Muller-Ladner U, Frey W, et al. Increased serum levels of non-collagenous matrix proteins (cartilage oligomeric matrix protein and melanoma inhibitory activity) in marathon runners. Osteoarthritis and Cartilage. 2000;8(3):222–229
  31. Kraus V, Wiggin D. Arthritis and exercise. In:  Ehrman J,  Gordan P,  Visich P,  Keteyian S editor. Clinical Exercise Physiology. Champaign, IL: Human Kinetics; 2003;
  32. Rossler A, Laszlo Z, Kvas E, Hinghofer-Szalkay HG. Plasma hyaluronan concentration: no circadian rhythm but large effect of food intake in humans. European Journal of Applied Physiology and Occupational Physiology. 1998;78(6):573–577
  33. Gineyts E, Mo JA, Ko A, et al. Effects of ibuprofen on molecular markers of cartilage and synovium turnover in patients with knee osteoarthritis. Annals of the Rheumatic Diseases. 2004;63(7):857–861
  34. Felson DT, Couropmitree NN, Chaisson CE, et al. Evidence for a mendelian gene in a segregation analysis of generalized radiographic osteoarthritis: The Framingham Study. Arthritis and Rheumatism. 1999;41(6):1064–1071
  35. Salminen H, Perala M, Lorenzo P, et al. Up-regulation of cartilage oligomeric matrix protein at the onset of articular cartilage degeneration in a transgenic mouse model of osteoarthritis. Arthritis and Rheumatism. 2000;43(8):1742–1748
  36. Matyas JR, Atley L, Ionescu M, et al. Analysis of cartilage biomarkers in the early phases of canine experimental osteoarthritis. Arthritis and Rheumatism. 2004;50(2):543–552
  37. Lindhorst E, Vail TP, Guilak F, et al. Longitudinal characterization of synovial fluid biomarkers in the canine meniscectomy model of osteoarthritis. Journal of Orthopaedic Research. 2000;18(2):269–280
  38. Dragomir AD, Kraus VB, Renner JB, et al. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis and Cartilage. 2002;10(9):687–691
  39. Aigner T, Bartnik E, Sohler F, Zimmer R. Functional genomics of osteoarthritis: on the way to evaluate disease hypotheses. Clinical Orthopaedics and Related Research. 2004;427(supplement):S138–S143
  40. Attur MG, Dave MN, Amin AR. Functional genomics approaches in arthritis. American Journal of Pharmacogenomics. 2004;4(1):29–43
  41. Loughlin J, Dowling B, Chapman K, et al. Functional variants within the secreted frizzled-related protein 3 gene are associated with hip osteoarthritis in females. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(26):9757–9762
  42. Smith AJ, Keen LJ, Billingham MJ, et al. Extended haplotypes and linkage disequilibrium in the IL1R1 IL1A IL1B IL1RN gene cluster: association with knee osteoarthritis. Genes and Immunity. 2004;5(6):451–460
  43. Kizawa H, Kou I, Iida A, et al. An aspartic acid repeat polymorphism in asporin inhibits chondrogenesis and increases susceptibility to osteoarthritis. Nature Genetics. 2005;37(2):138–144[Epub 2005 Jan 09]
  44. Pelletier JP. Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis. Osteoarthritis and Cartilage. 2004;12(supplement A):S63–S68
  45. Liebman M. An engineerting approach to translational medicine. American Scientist. 2005;July/August:296–298
  46. Kong S, Stabler T, Criscione L et al. Diurnal variation of biomarkers in patients with radiographic knee osteoarthritis. Osteoarthritis and Cartilage, in press.

PII: S1521-6942(05)00102-6

doi: 10.1016/j.berh.2005.09.001

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 1 , Pages 69-80 , February 2006

Article Tools

* Image Usage & Resolution